Primary in vitro and in vivo evaluation of norcantharidin-chitosan/poly (vinyl alcohol) for cancer treatment

Drug Delivery

Volumn 21, Issue 4, 2014, Pages 293-301

  Li, Mingna ^a   Xu, Xiaofen ^a   Lu, Fei ^b   Guo, Shengrong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor drug; Norcantharidin; Norcantharidin chitosan; Norcantharidin poly (vinyl alcohol); Polymer drug conjugate

Indexed keywords

CASPASE 3; CASPASE 8; CHITOSAN; NORCANTHARIDIN; POLYVINYL ALCOHOL; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS;

ALCOHOLYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONJUGATE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENZYME ACTIVATION; EVALUATION STUDY; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; TUMOR MODEL; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CHITOSAN; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MICE; POLYVINYL ALCOHOL; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901946213     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.840692     Document Type: Article

References (27)

1. Chang C, Zhu Y, Tang X, et al. (2011). The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture. Mol Biol Rep 38:163-9.
2. Chen YN, Cheng CC, Chen JC, et al. (2003). Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-Jun- NH2-terminal kinase signaling pathways in human hepatoma HepG2 cells. Br J Pharmacol 140:461-70.
3. Chen Y-R, Wang W, Kong A-N-T, et al. (1998). Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J Biol Chem 273:1769-75. (Pubitemid 28133709)
4. Cobleigh MA, Langmuir VK, Sledge GW, et al. (2003). A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30:117-124. (Pubitemid 37433402)
5. Guan M, Zhou Y, Zhu QL, et al. (2012a). N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy. Nanomedicine 8:1172-81.
6. Guan M, Zhu QL, Liu Y, et al. (2012b). Uptake and transport of a novel anticancer drug-delivery system: lactosyl-norcantharidin-associated N-trimethyl chitosan nanoparticles across intestinal Caco-2 cell monolayers. Int J Nanomed 7:1921-30.
7. Homsi J, Simon GR, Garrett CR, et al. (2007). Phase I trial of poly-Lglutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 13:5855-61. (Pubitemid 47583911)
8. Huang Y, Liu Q, Liu K, et al. (2009). Suppression of growth of highlymetastatic human breast cancer cells by norcantharidin and its mechanisms of action. Cytotechnology 59:201-8.
9. Khandare J, Minko T. (2006). Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 31:359-97.
10. Kok S-H, Cheng S-J, Hong C-Y, et al. (2005). Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett 217:43-52. (Pubitemid 39642865)
11. Liao H-F, Chen Y-J, Chou C-H, et al. (2011). Norcantharidin induces cell cycle arrest and inhibits progression of human leukemic Jurkat T cells through mitogen-activated protein kinase-mediated regulation of interleukin-2 production. Toxicol Vitro 25:206-12.
12. Luan J, Duan J, Liu Q, et al. (2010). Inhibitory effects of norcantharidin against human lung cancer cell growth and migration. Cytotechnology 62:349-55.
13. Maeda H, Sawa T, Konno T. (2001). Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47-61. (Pubitemid 32727608)
14. Mahmoudi M, Simchi A, Imani M, et al. (2008). Optimal design and characterization of superparamagnetic iron oxide nanoparticles coated with polyvinyl alcohol for targeted delivery and imaging. J Phys Chem B 112:14470-81.
15. Matsumura Y, Maeda H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-92. (Pubitemid 17221789)
16. McCluskey A, Ackland SP, Bowyer MC, et al. (2003). Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg Chem 31:68-79. (Pubitemid 36411927)
17. Peng C, Liu X, Xu K, et al. (2009). Norcantharidin induces HT-29 colon cancer cell apoptosis through the avb6-extracellular signal-related kinase signaling pathway. Cancer Sci 100:2302-8.
18. Peng F, Wei YQ, Tian L, et al. (2002). Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol 128:223-30. (Pubitemid 34280381)
19. Pili R, Rosenthal PN, Van Hazel G, et al. (2010). Phase II study on the addition of ASA404 (vadimezan; 5, 6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 16:2906-14.
20. Thistlethwaite AJ, Leeper DB, Moylan III DJ, et al. (1985). pH distribution in human tumors. Int J Radiat Oncol Biol Phys 11: 1647-52. (Pubitemid 15233627)
21. Vasey PA, Kaye SB, Morrison R, et al. (1999). Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin Cancer Res 5:83-94. (Pubitemid 29045181)
22. Wang G-S. (1989). Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 26:147-62. (Pubitemid 19257209)
23. Wang Q, Zhang L, Hu W, et al. (2010). Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery. Nanomedicine 6:371-81.
24. Whitmarsh A, Davis R. (1996). Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74:589-607. (Pubitemid 26343761)
25. Yu D, Bei Y, Chen X, et al. (2011). Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption. 5th International Conference on Bioinformatics and Biomedical Engineering (iCBBE) 2011, IEEE.
26. Zhang L, Sun X, Zhang Z-R. (2005). An investigation on livertargeting microemulsions of norcantharidin. Drug Deliv 12:289-95.
27. Zhang H, Mardyani S, Chan W-CW, et al. (2006). Design of biocompatible chitosan microgels for targeted pH-mediated intracellular release of cancer therapeutics. Biomacromolecules 7: 1568-72. (Pubitemid 43811214)